Elilly由于销售强劲,提高了2025年的利润预测,但其股票在一种新的药物表现不佳后下降。 Eli Lilly raised its profit forecast for 2025 due to strong sales, but its stock dropped after a new drug underperformed.

Elilily提高了2025年的利润预测,原因是其减重药物Zepbound和Mounjaro销售量强劲,预计每股收入在21.75美元至23美元之间,从20.78美元增至22.28美元。 Eli Lilly upped its 2025 profit forecast due to strong sales of its weight-loss drug, Zepbound, and Mounjaro, projecting earnings between $21.75 to $23 per share, up from $20.78 to $22.28. 据该公司报告,在Zepbound和Mounjaro的推动下,在问题2中,收入增长了38%,达到155.6亿美元。 The company reported a 38% revenue increase to $15.56 billion in Q2, driven by Zepbound and Mounjaro. 尽管财务结果好,但Eli Lilly的股价在其试验性减肥药,或forglipron,显示结果低于市场预期后下跌. Despite the positive financial results, Eli Lilly's stock fell after its experimental weight-loss pill, orforglipron, showed results below market expectations.